IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00Inhibikase Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: SP IKT Holdings Reports 8.69% Passive Stake In Inhibikase Therapeutics Inc As Of Oct 21
Brief: Inhibikase Therapeutics Closes Up To $275 Million Financing
Brief: Commodore Capital LP Reports 9.99% Passive Stake In Inhibikase Therapeutics Inc As Of Oct 9, 2024- SEC Filing
Brief: Inhibikase Therapeutics Says On October 9 Co Entered Into Securities Purchase Agreement In Connection With A Private Placement
Brief: Point72 Asset Management Reports 8.4%Passive Stake In Inhibikase Therapeutics As Of Oct 9- SEC Filing
Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Inhibikase Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Completes Enrollment Of Phase 2 Trial Evaluating Risvodetinib In Untreated Parkinson’S Disease
Brief: Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million
Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Intends To Vigorously Dispute Pivot's Claims And Assert Counterclaims Against Pivot
Brief: Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs
Brief: Inhibikase Therapeutics Announces Pre-IND Meeting With The FDA For IkT-001Pro In Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics To Provide Trial Update For Risvodetinib On March 9